Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

2.

These Athletes Weren't Doping. Their Genes Made It Look Like They Did.

3.

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

4.

Loneliness and social isolation linked to heightened risk of death in those with cancer

5.

Smartphone App Detects Eye Cancers From Photos


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot